These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 15297431)

  • 1. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
    Lee KW; Kim JH; Park JH; Kim HP; Song SH; Kim SG; Kim TY; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
    Anticancer Res; 2006; 26(5A):3429-38. PubMed ID: 17094463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.
    Ryu JK; Lee WJ; Lee KH; Hwang JH; Kim YT; Yoon YB; Kim CY
    Cancer Lett; 2006 Jun; 237(1):143-54. PubMed ID: 16009488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
    Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
    Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
    Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
    Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
    Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
    Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
    Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
    Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
    Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
    Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia.
    Kim BS; Bae E; Kim YJ; Ahn KS; Park J; Rhee JY; Lee YY; Kim Y; Lee D; Kim BK; Yoon SS
    Anticancer Drugs; 2007 Jul; 18(6):641-7. PubMed ID: 17762392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
    Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
    Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential protein acetylation induced by novel histone deacetylase inhibitors.
    Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
    Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
    Ahn MY; Jung JH; Na YJ; Kim HS
    Gynecol Oncol; 2008 Jan; 108(1):27-33. PubMed ID: 17920664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
    Ahn MY; Chung HY; Choi WS; Lee BM; Yoon S; Kim HS
    Int J Oncol; 2010 Jan; 36(1):125-31. PubMed ID: 19956841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
    Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
    Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
    Glick RD; Swendeman SL; Coffey DC; Rifkind RA; Marks PA; Richon VM; La Quaglia MP
    Cancer Res; 1999 Sep; 59(17):4392-9. PubMed ID: 10485488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
    Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
    Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.